Drug
onabotulinumtoxin A
onabotulinumtoxin A is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
60%(3 trials)
Phase Distribution
Ph early_phase_1
1
17%
Ph phase_3
1
17%
Ph not_applicable
2
33%
Ph phase_4
2
33%
Phase Distribution
1
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
2(33.3%)
N/ANon-phased studies
2(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(5)
Other(1)
Detailed Status
Completed5
Suspended1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (16.7%)
Phase 31 (16.7%)
Phase 42 (33.3%)
N/A2 (33.3%)
Trials by Status
suspended117%
completed583%
Recent Activity
0 active trials
Showing 5 of 6
suspendedearly_phase_1
Feasibility of BOTOX Injection on Improving Female Stress Urinary Incontinence
NCT04984317
completedphase_4
Prevention of Bladder Dysfunction in Acute Spinal Cord Injury
NCT01698138
completednot_applicable
Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines
NCT05089851
completednot_applicable
Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain
NCT02369068
completedphase_4
Intravesicular Onabotulinumtoxin A in Interstitial Cystitis
NCT02297100
Clinical Trials (6)
Showing 6 of 6 trials
NCT04984317Early Phase 1
Feasibility of BOTOX Injection on Improving Female Stress Urinary Incontinence
NCT01698138Phase 4
Prevention of Bladder Dysfunction in Acute Spinal Cord Injury
NCT05089851Not Applicable
Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines
NCT02369068Not Applicable
Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain
NCT02297100Phase 4
Intravesicular Onabotulinumtoxin A in Interstitial Cystitis
NCT02165111Phase 3
Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6